Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

J. E. Rosenberg, S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. J. Hohl, F. Millard, D. F. Bajorin, E. J. Small

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207'. Together they form a unique fingerprint.

Medicine & Life Sciences